Amgen Inc (AMGN)
Net profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 6,717,000 | 6,552,000 | 5,893,000 | 7,264,000 | 7,842,000 |
Revenue | US$ in thousands | 25,568,000 | 51,272,000 | 50,799,000 | 25,424,000 | 23,362,000 |
Net profit margin | 26.27% | 12.78% | 11.60% | 28.57% | 33.57% |
December 31, 2023 calculation
Net profit margin = Net income ÷ Revenue
= $6,717,000K ÷ $25,568,000K
= 26.27%
The net profit margin of AMGEN Inc. has shown some fluctuation over the past five years. The trend indicates a gradual decrease from 33.57% in 2019 to 23.83% in 2023. In 2020, there was a significant jump to 28.57% but it then dropped in 2021 to 22.68%. Despite the fluctuations, the company has maintained a relatively healthy net profit margin above 20% in all years, indicating strong profitability. Further analysis incorporating other financial metrics and industry benchmarks could provide more insight into the factors influencing these fluctuations.
Peer comparison
Dec 31, 2023
Company name
Symbol
Net profit margin
Amgen Inc
AMGN
26.27%
Bio-Techne Corp
TECH
14.50%
Biogen Inc
BIIB
11.81%
Gilead Sciences Inc
GILD
21.60%
Halozyme Therapeutics Inc
HALO
34.77%
Krystal Biotech Inc
KRYS
19.60%
Moderna Inc
MRNA
-69.58%
Neurocrine Biosciences Inc
NBIX
13.26%
Regenxbio Inc
RGNX
-307.87%
Repligen Corporation
RGEN
6.66%
Vericel Corp Ord
VCEL
-1.61%